Poniard Plans 2009 NDA For "New Generation" Platinum Chemo Picoplatin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Poniard Pharmaceuticals plans to submit an NDA for its "new generation" platinum-based cancer therapy picoplatin in the first half of 2009, CEO Jerry McMahon told investors at the Lazard Capital Markets Healthcare Conference Nov. 27
You may also be interested in...
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.